I think it would be fair and appropriate for Neoprobe's Lymphoseek partner Cardinal Health,to make some sort of statement pertaining to their continued confidence on the path Neoprobe/Lymphoseek is taking to regulatory approval... I dont think we heard any statements from Cardinal as of yet.I think that would surely build up Shareholder confidence and pipe down the haters a little bit if Cardinal would just say anything' positive. I surely would love a Cardinal Health rep to speak on Lymphoseek's behalf. I have notified CEO Mark Pykett of my thought and suggestion. GLTA
CAH will say everything it needs to say when it starts distribution. The PET specialists and other NPS reps have met and discussed Lymphoseek and have been told there is plenty of it available for distribution.
All that needs to happen is for the FDA to approve it, and price point established.
We as shareholders are concerned with one thing and thats value on our investment. It's all about the share price -- Even just one positive sentence from CAH can go a long way- Now if you want to say this is a plan by potential buyout suitors to intentionally try to lower share price and buy company on the cheap? well that may be sensical..